Somatostatin Analogs

Aetna covers somatostatin analogs for acromegaly (high pretreatment IGF‑1 with inadequate/partial response to or contraindication to surgery/radiotherapy), symptomatic carcinoid syndrome, AIDS‑associated severe secretory diarrhea after antimicrobials/antimotility agents fail (octreotide), Grade ≥3 cancer‑related diarrhea (octreotide), and congenital/persistent hyperinsulinemic hypoglycemia of infancy (octreotide/Sandostatin); all other uses are considered experimental/investigational and excluded. Key requirements: precertification is required for octreotide, lanreotide, and pasireotide, and for acromegaly Signifor LAR and lanreotide injection are only covered if the member has contraindication, intolerance, or inadequate response to the specified alternative somatostatin analogs.

"Signifor LAR (pasireotide pamoate): "Treatment of patients with acromegaly who have had an inadequate response to surgery and/or for whom surgery is not an option" (FDA‑approved indication, text)"